ERBB2 and lung adenocarcinoma: Data published by the Memorial Sloan Kettering Cancer Center and the University of Colorado in 2016 showed that HER2 amplification was detected in 5 out of 175 lung adenocarcinoma patients (3%) without targeted therapy, while HER2 mutations were detected in 4 out of 148 patients (3%).